Phase 1 study of irinotecan and cisplatin with concurrent thoracic radiotherapy in patients with limited-disease small cell lung cancer (LD-SCLC).
Completed
- Conditions
- imited-disease small cell lung cancer (LD-SCLC).
- Registration Number
- NL-OMON23572
- Lead Sponsor
- Department of Medical OncologyErasmus University Medical Center / Daniel den Hoed Kliniek3008 AE ROTTERDAM
- Brief Summary
ung Cancer. 2008 Jul;61(1):123-8. Epub 2008 Jan 7.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 9
Inclusion Criteria
1. Cytologically or histologically proven SCLC;
2. Disease confined to one hemithorax without evidence of cytologically proven malignant pleural effusion;
Exclusion Criteria
1. Other serious ilnesses;
2. Concurrent therapy with other anti-cancer drugs;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The aim of the study is to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of irinotecan and cisplatin with concurrent thoracic radiotherapy in patients with LD-SCLC ias a onve every three weeks schedule.
- Secondary Outcome Measures
Name Time Method To determine the efficacy and progression-free and overall survival of irinotecan and cisplatin with concurrent thoracic radiotherapy in patients with LD-SCLC.